Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain, has announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2024. The company reported significant growth in revenue and expansion of its healthcare network.
Q3 FY25 Financial Highlights:
- Revenue from operations stood at INR 431 crore, marking a 29.5% year-on-year (YoY) growth.
- Revenue from operations in India reached INR 390 crore, a 34.5% YoY increase.
- Revenue from mature facilities totalled INR 291 crore, growing by 16.6% YoY.
- EBITDA stood at INR 128 crore, up 26.3% YoY, with an EBITDA margin of 28.8%.
- Profit after tax (PAT) was INR 28 crore, reflecting a 25% YoY increase, with a PAT margin of 6.4%.
- The company operated 221 facilities as of December 31, 2024, with 12 new facilities added during the quarter.
9M FY25 Financial Highlights:
- Revenue from operations for the nine-month period stood at INR 1,251 crore, a 27.2% YoY growth.
- Revenue from operations in India was INR 1,124 crore, reflecting a 31.7% YoY rise.
- Revenue from mature facilities reached INR 874 crore, growing by 15% YoY.
- The company’s revenue composition included 79.9% from services such as surgeries, consultations, and treatments, while 20.1% came from product sales, including optical and pharmaceutical products.
- EBITDA stood at INR 356 crore, up 27.5% YoY, with an EBITDA margin of 27.8%.
- PAT was INR 68 crore, increasing by 26.2% YoY, with a PAT margin of 5.3%.
- The company expanded its network with 42 new facilities in 9M FY25, including 35 newly established centres and seven acquisitions.
- A total of 213,602 surgeries were performed during the period, a 31.8% YoY increase.
Strategic Growth and Expansion
Dr. Agarwal’s Health Care continues its expansion strategy, leveraging its expertise in eye care and medical technology. The company remains focused on increasing accessibility and improving healthcare delivery across its facilities.
